United States
US 12,697,369 B2
Targeting CD24-Siglec interactions for the treatment of nonviral hepatitis and liver fibrosis
US 12,697,369 B2 is a granted patent from the United States Patent and Trademark Office (USPTO), dated 2026-08-04. Applicant: University of Maryland, Baltimore; Oncolmmune, Inc. Its PDF downloads from this page without an account, up to 5 a day.
- Applicant
- University of Maryland, Baltimore; Oncolmmune, Inc.
- Inventors
- Yang Liu; Pan Zheng; Xu Wang; Mingyue Liu; Martin Devenport
- Publication date
- 2026-08-04
- Filing date
- 2021-08-05
- Document type
- B2 Granted patent
- Also written as
- US 12,697,369 B2 · US12697369 · 12697369
Abstract
Provided herein are methods and compositions for the prevention and treatment of nonalcoholic steatohepatitis (NASH) by targeting the CD24-Siglec axis.
The opening of the abstract. The full text is in the PDF.
No account needed: 5 free downloads a day (5 left today). Batch downloads and Office Action citations need a free account.
Patent office website: United States Patent and Trademark Office (USPTO)
Look up another patent
Need many patents at once?
Paste a whole list of numbers. DownloadPatent finds the right version of each and packs the PDFs into one ZIP.
Sign up free